David M. Briere

4.4k total citations
21 papers, 370 citations indexed

About

David M. Briere is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David M. Briere has authored 21 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David M. Briere's work include Cancer-related gene regulation (5 papers), Biochemical and Molecular Research (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). David M. Briere is often cited by papers focused on Cancer-related gene regulation (5 papers), Biochemical and Molecular Research (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). David M. Briere collaborates with scholars based in United States. David M. Briere's co-authors include Peter Olson, James G. Christensen, Jill Hallin, Ruth Aranda, Lars D. Engstrom, Niranjan Sudhakar, Andressa L. Sodré, David Woods, Harrah Chiang and Jeffrey S. Weber and has published in prestigious journals such as Cancer Research, BMC Genomics and Molecular Cancer Therapeutics.

In The Last Decade

David M. Briere

18 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David M. Briere United States	7	232	181	128	75	44	21	370
Hengyu Lu United States	8	158 0.7×	111 0.6×	55 0.4×	52 0.7×	51 1.2×	11	269
Andy Protter United States	5	150 0.6×	158 0.9×	60 0.5×	50 0.7×	38 0.9×	7	261
Chuandong Geng United States	6	309 1.3×	136 0.8×	232 1.8×	57 0.8×	132 3.0×	7	485
Candice McCoy United States	11	286 1.2×	233 1.3×	171 1.3×	106 1.4×	52 1.2×	27	501
Subhasree Balakrishnan United States	3	211 0.9×	88 0.5×	76 0.6×	32 0.4×	79 1.8×	3	299
Sonia Garofalo Italy	6	145 0.6×	189 1.0×	126 1.0×	74 1.0×	50 1.1×	7	364
Susan D’Aloisio Canada	4	262 1.1×	140 0.8×	130 1.0×	24 0.3×	89 2.0×	7	408
Matthew Tanner United States	7	200 0.9×	75 0.4×	90 0.7×	103 1.4×	129 2.9×	8	342
M Kůta Czechia	3	205 0.9×	224 1.2×	152 1.2×	36 0.5×	47 1.1×	5	382
Martuza Sarwar Sweden	8	204 0.9×	64 0.4×	102 0.8×	23 0.3×	73 1.7×	10	299

Countries citing papers authored by David M. Briere

Since Specialization

Citations

This map shows the geographic impact of David M. Briere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Briere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Briere more than expected).

Fields of papers citing papers by David M. Briere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Briere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Briere. The network helps show where David M. Briere may publish in the future.

Co-authorship network of co-authors of David M. Briere

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Briere. A scholar is included among the top collaborators of David M. Briere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Briere. David M. Briere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sudhakar, Niranjan, Jade Laguer, David M. Briere, et al.. (2024). Abstract 7268: The SOS1 inhibitor MRTX0902 demonstrates activity across cancer models with mutations in proximal components of the RAS-MAPK pathway. Cancer Research. 84(6_Supplement). 7268–7268.

Negrão, Marcelo V., David Molkentine, Laura D. Hover, et al.. (2024). Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC. Cancer Research. 84(6_Supplement). 1212–1212.

Waters, Laura, Ruth Aranda, Krystal Moya, et al.. (2024). Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers. Cancer Research. 84(6_Supplement). 3319–3319. 2 indexed citations

Hoffman, Natalie, Andrew Calinisan, David M. Briere, et al.. (2024). Abstract 4448: Effects of adagrasib on cholesterol, lipid and glucose gene expression regulation in tumor xenograft models and patient samples. Cancer Research. 84(6_Supplement). 4448–4448. 1 indexed citations

Sudhakar, Niranjan, Jade Laguer, David M. Briere, et al.. (2023). Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC. Cancer Research. 83(7_Supplement). 3499–3499.

Waters, Laura, Ruth Aranda, Krystal Moya, et al.. (2023). Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers. Cancer Research. 83(7_Supplement). 2779–2779. 1 indexed citations

Briere, David M., Shuai Li, Andrew Calinisan, et al.. (2021). The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Molecular Cancer Therapeutics. 20(6). 975–985. 109 indexed citations

Smith, Christopher R., Svitlana Kulyk, Lars D. Engstrom, et al.. (2021). Abstract LB003: Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors. Cancer Research. 81(13_Supplement). LB003–LB003. 10 indexed citations

Smith, Christopher R., Lars D. Engstrom, Svitlana Kulyk, et al.. (2021). Abstract P165: MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models. Molecular Cancer Therapeutics. 20(12_Supplement). P165–P165. 2 indexed citations

10.

Hansen, Ryan J., Steven V. Horton, E. Lorena Mora‐Blanco, et al.. (2021). Abstract LBA005: Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors. Molecular Cancer Therapeutics. 20(12_Supplement). LBA005–LBA005. 1 indexed citations

11.

Daemen, Anneleen, Jessica D. Sun, Aleksandr Pankov, et al.. (2021). Abstract 1131: ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models. Cancer Research. 81(13_Supplement). 1131–1131. 3 indexed citations

12.

Marx, Matthew A., Brian R. Baer, Joshua A. Ballard, et al.. (2020). Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer. Molecular Cancer Research. 18(5_Supplement). B30–B30. 5 indexed citations

13.

Hallin, Jill, Andrew Calinisan, Lauren Hargis, et al.. (2020). Abstract LB-098: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models. Cancer Research. 80(16_Supplement). LB–98. 1 indexed citations

14.

Christensen, James G., Jay B. Fell, Matthew A. Marx, et al.. (2019). Abstract LB-271: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor. LB–271. 2 indexed citations

15.

Christensen, James G., Jay B. Fell, Jill Hallin, et al.. (2019). Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers. Molecular Cancer Therapeutics. 18(12_Supplement). C069–C069. 5 indexed citations

16.

Briere, David M., Andrew Calinisan, Ruth Aranda, et al.. (2019). Abstract LB-C09: The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model. Molecular Cancer Therapeutics. 18(12_Supplement). LB–C09. 10 indexed citations

17.

Briere, David M., Niranjan Sudhakar, David Woods, et al.. (2017). The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunology Immunotherapy. 67(3). 381–392. 117 indexed citations

18.

Kuruma, Hidetoshi, Hiroaki Matsumoto, Masaki Shiota, et al.. (2013). A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo. Molecular Cancer Therapeutics. 12(5). 567–576. 86 indexed citations

19.

Briere, David M., et al.. (2013). Abstract C264: Effective preclinical treatment of KRAS mutant lung cancers with a combination of MLN0128, an investigational novel mTORC1/2 inhibitor, and a selective MEK inhibitor.. Molecular Cancer Therapeutics. 12(11_Supplement). C264–C264. 1 indexed citations

20.

Zhu, Zhou, Wenyue Hu, Heather Estrella, et al.. (2012). Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding. BMC Genomics. 13(1). 355–355. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact